WCLC 2025 - Posters & ePosters-P3.18.38 Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC With PD-L1 TC <50%

P3.18.38 Phase 3 eVOLVE-Lung02 Trial of Volrustomig + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic NSCLC With PD-L1 TC <50%

Asset Subtitle

Melissa Johnson

Meta Tag

Speaker Melissa Johnson

Topic Clinical Trials in Progress